California startup lands $20M to support bioresorbable scaffold

October 9, 2013 by Arezu Sarvestani

Amaranth Medical raises $20 million in a Series B financing round to help the company chase European regulatory approval for its Fortitude bioresorbable scaffold.

California startup lands $20M to support bioresorbable scaffold

Mountain View, Calif.-based Amaranth Medical announced a $20 million Series B funding round in support of development of the company's flagship Fortitude bioresorbable scaffold, a device-based treatment for coronary artery disease.

Amaranth plans to use the funds to further progress in clinical trials in hopes of winning CE Mark approval in the European Union, according to a company statement.

Sign up to get our free newsletters delivered right to your inbox.

The company has already competed enrollment in the clinical trial and plans to release preliminary results later this year at the Transcatheter Cardiovascular Therapeutics in San Francisco.

Funding was lead by new investor DCP Management, a Singapore firm. Venstar Capital also joined in funding for the 1st time, alongside existing investors Bio*One Capital, Charter Life Sciences and Phillip Capital, according to a press release.